

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
KDL GmbH	01/13/2009
Dr. Shitotomo Yamauchi	01/09/2009
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	INTERMUNE, INC.
<b>Street Address:</b>	3280 Bayshore Boulevard
<b>City:</b>	Brisbane
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94005-1021
<b>PROPERTY NUMBERS Total: 8</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	09044441
Application Number:	09364562
Application Number:	09162011
Application Number:	09563063
Application Number:	09239211
Application Number:	09724378
Application Number:	10204605
Application Number:	07947995
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)474-0448
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Email:</b>	wsalgado@marshallip.com
<b>Correspondent Name:</b>	Waleska Salgado
<b>Address Line 1:</b>	233 South Wacker Drive, Suite 6300
<b>Address Line 4:</b>	Chicago, ILLINOIS 60606

OP \$320.00 09044441

**PATENT**

ATTORNEY DOCKET NUMBER:

30481/G1000

NAME OF SUBMITTER:

Shelley C. Danek

**Total Attachments: 9**

source=Assignment#page1.tif

source=Assignment#page2.tif

source=Assignment#page3.tif

source=Assignment#page4.tif

source=Assignment#page5.tif

source=Assignment#page6.tif

source=Assignment#page7.tif

source=Assignment#page8.tif

source=Assignment#page9.tif

**Confirmatory Assignment**

This Assignment ("Assignment") is entered into between KDL GmbH ("KDL GmbH"), a Swiss corporation, Dr. Shitotomo Yamauchi, (collectively with KDL, "Assignors") and InterMune, Inc. ("Assignee"), a Delaware corporation. This Assignment is effective as of November 21, 2007.


For good and valuable consideration previously received, the receipt and sufficiency of which is hereby acknowledged, each Assignor does hereby sell, assign and transfer unto Assignee all of its right, title and interest in and to the patents and patent applications listed in Exhibit A hereto (collectively "Patents"), the inventions described in the Patents, and any U.S. or foreign applications or patents based or granted on said inventions, or any parts thereof, and any U.S. or foreign applications, except for Japan, Korea, and Taiwan, or patents claiming priority based on the Patents, including continuations, continuations in part, divisions, reexaminations, reissues, substitutes, renewals or extensions of any of the foregoing, including all rights of priority under the International Convention for the Protection of Industrial Property, and all rights to sue for damages and other remedies in respect of any infringement of such U.S. or foreign applications or patents or other acts within the scope of the claims of any published specifications of such U.S. or foreign applications.


The undersigned signing on behalf of KDL GmbH warrants s/he is authorized to execute this document on behalf of KDL GmbH.

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Assignment.

On behalf of KDL GmbH

Dr. Shitotomo Yamauchi

Signature: 

Signature: 

Name: KJETIL H. GAUSTAD


Date: Jan. 9, 2009


Title: Managing Director

Date: January 13, 2009

WITNESSES:


WITNESSES:


Signature: 

Signature: 

Name: KATARINA LIF BURREN

Name: TETSUJI ASAO

Signature: 

Signature: 

Name: Sara Aiiodi

Name: YASUTOMO YAMAUCHI


## LEGALIZATION

The undersigned **Peter Meyer**, notary public at Schöffland (Switzerland) attests the authenticity of the signature of

**Mr Kjell Gaustad**, 14.09.1942, from Switzerland, in 4104 Oberwil, Rütimattstrasse 5

Aarau, 13 January 2009

The notary:



**Exhibit A**

<b>Title</b>	<b>Country</b>	<b>Serial No.</b>	<b>Matter Filing Date</b>	<b>Patent No.</b>	<b>Issue Date</b>
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	AU	72399/96	9/17/1996	709178	12/9/1999
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	BR	PI9610480-5	9/17/1996		
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	CA	2232191	9/17/1996		
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	EPO	96933808.6	9/17/1996	0866656	4/25/2007
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	FR	96933808.6	9/17/1996	0866656	4/25/2007
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	DE	96933808.6	9/17/1996	69637050.6	4/25/2007

Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	GB	96933808.6	9/17/1996	0866656	4/25/2007
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	IT	96933808.6	9/17/1996	0866656	4/25/2007
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	MX	1998/002150	9/17/1996	206777	2/18/2002
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	ZA	96/7880	9/18/1996	96/7880	6/25/1997
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	US	09/044441	3/19/1998	5962478	10/5/1999
COMPOSITIONS AND METHODS FOR INHIBITION OF THE PATHOPHYSIOLOGIC ACTIONS IN MAMMALS OF TUMOR NECROSIS FACTOR-ALPHA	US	09/364562	7/30/1999	6300349	10/9/2001
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	AU	53005/96	3/4/1996	697742	1/28/1999

Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	BR	PI9607541-4	3/4/1996		
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	CA	2214531	3/4/1996		
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	EPO	96909547.0	3/4/1996	0813409	5/6/2004
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	FR	96909547.0	3/4/1996	0813409	5/6/2004
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	DE	96909547.0	3/4/1996	69632396.6	5/6/2004
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	GB	96909547.0	3/4/1996	0813409	5/6/2004
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	IT	96909547.0	3/4/1996	0813409	5/6/2004
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	MX	976689	3/4/1996	214372	5/22/2003
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	ZA	96/7801	9/16/1996	96/7801	6/25/1997
TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS	US	09/162011	9/28/1998	6090822	7/18/2000
COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANT OR BENIGN TUMOR DISORDERS	US	09/563063			
TREATMENT OF LYMPHOMAS, LEUKEMIAS, BREAST CARCINOMAS, ASTROCYTOMAS,	AU	66061/00	7/18/2000	784523	8/10/2006

Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
TREATMENT OF LYMPHOMAS, LEUKEMIAS, BREAST CARCINOMAS, ASTROCYTOMAS,	CA	2388840	7/18/2000		
TREATMENT OF BREAST CARCINOMAS, ASTROCYTOMAS, MELANOMAS AND RELATED	EPO	00953647.5	7/18/2000		
TREATMENT OF BREAST CARCINOMAS, ASTROCYTOMAS, MELANOMAS AND RELATED	HK	03102119.9	7/18/2000		
COMPOSITIONS AND METHOD FOR TREATMENT OF LYMPHOMAS, LEUKEMIAS, AND	US	09/239211	1/28/1999	6114353	9/5/2000
METHODS FOR TREATMENT OF BENIGN AND MALIGNANT TUMORS, INCLUDING LYMPHOMAS,	US	09/724378	1/28/1999	RE40155	3/18/2008
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	AU	2000237125	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	CA	2400491	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	EPO	00915942.7	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	IL	151403	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	MX	2002/008132	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	NZ	521518	2/21/2000	521518	4/7/2005



Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	NO	20023944	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	ZA	2002/6651	2/21/2000	2002/6651	10/29/2003
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	TR	2002/02033	2/21/2000		
COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY	US	10/204605	12/10/2002	6956044	10/18/2005
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	AU	49812/90	2/15/1990	633541	5/28/1993
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	AT	90903464.7	1/26/1990	0458861	4/3/1996
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	BR	PI9003771-5	8/1/1990		
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	CA	2010017	2/14/1990	2010017	9/5/1995
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	DK	90903464.7	1/26/1990	0458861	4/3/1996
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	EPO	90903464.7	1/26/1990	0458861	4/3/1996
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	NL	90903464.7	1/26/1990	0458861	4/3/1996
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	NZ	232559			
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	SE	90903464.7	1/26/1990	0458861	4/3/1996

Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	CH	90903464.7	1/26/1990	0458861	4/3/1996
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	US	07/947995	9/21/1992	5310562	5/10/1994
COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS	NZ	336361	6/18/1999		
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	BE	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	EPO	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	FR	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	DE	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	GB	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	IT	90301607.9	2/15/1990	0383591	11/21/2001
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	MX	21719	7/24/1990	182266	7/29/1996
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	NZ	266673	5/9/1994	266673	5/9/1994

Title	Country	Serial No.	Matter Filing Date	Patent No.	Issue Date
USE OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE IN THE PREVENTION OF FIBROTIC	ES	90301607.9	2/15/1990	0383591	11/21/2001
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	BE	01107235.2	2/15/1990	1138329	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	EPO	01107235.2	2/15/1990	1138329	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	FR	01107235.2	2/15/1990	1138329	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	DE	01107235.2	2/15/1990	69034143.1	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	GB	01107235.2	2/15/1990	1138329	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	IT	01107235.2	2/15/1990	1138329	6/2/2004
COMPOSITION CONTAINING 5-METHYL-1-PHENYL-2-(1 H)-PYRIDONE FOR REPARATION	ES	01107235.2	2/15/1990	1138329	6/2/2004